证券日报网讯 11月24日晚间，昂利康发布公告称，选举吴哲华先生为公司第四届董事会职工代表董 事。 （文章来源：证券日报） ...

Group 1 - The core point of the article is that Anglikon (SZ 002940) held its 14th meeting of the 4th board of directors on November 24, 2025, to discuss the election of a director for company affairs [1] - For the first half of 2025, Anglikon's revenue composition is entirely from the pharmaceutical manufacturing industry, accounting for 100.0% [1] - As of the report date, Anglikon's market capitalization is 7.9 billion yuan [1] Group 2 - The article also mentions that Dapeng Industrial's strategic placement has significantly benefited its insiders, with a subscription price of 9 yuan and a first-day listing price of 118 yuan, resulting in a floating profit of 24.92 million yuan for the actual controller and his brother [1]

昂利康公告称，2025年11月24日，公司2025年第二次临时股东大会召开。公司股权登记日股份总数 201,728,186股，其中回购股份5,619,700股无表决权，有表决权股份总数196,108,486股。出席会议的股东 及股东代表294名，代表有表决权股份93,527,063股，占比47.6915%。会议以现场记名投票表决和网络 投票结合方式，审议通过《关于修订的议案》等11项议案，律师认为会议各项程序及表决结果合法有 效。 ...

一、非独立董事辞任情况 浙江昂利康制药股份有限公司（以下简称"公司"）董事会于 2025 年 11 月 24 日收到公司非独立董事吴哲华先生提交的书面辞职报告。吴哲华先生因公司 内部工作调整，向公司董事会申请辞去第四届董事会非独立董事职务，同时一并 辞去董事会专门委员会职务，辞职后仍担任公司其他职务。根据《中华人民共和 国公司法》（以下简称"《公司法》"）及《公司章程》等相关规定，吴哲华先 生的辞任不会导致公司董事会成员低于法定最低人数，不会影响公司董事会的正 常运作，其辞职报告自送达公司董事会时生效。 证券代码：002940 证券简称：昂利康 公告编号：2025-090 浙江昂利康制药股份有限公司 关于非独立董事辞任暨选举第四届董事会 职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江昂利康制药股份有限公司 董 事 会 二、选举职工代表董事情况 根据《公司法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》等相关法律法规、规范性文件及《公司章程》的有关规定，公 司于 2025 年 11 月 24 日召开了职工代 ...

证券代码：002940 证券简称：昂利康 公告编号：2025-089 浙江昂利康制药股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示 1、为尊重中小投资者利益，提高中小投资者对公司股东大会审议的重大事 项参与度，本次股东大会审议的部分议案对中小投资者实行单独计票。中小投资 者是指除以下股东以外的其他股东：（1）上市公司的董事、监事、高级管理人员； （2）单独或者合计持有上市公司 5%以上股份的股东； 2、本次股东大会无否决或修改议案情况； 3、本次股东大会没有涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 现场会议召开时间：2025 年 11 月 24 日下午 14：00 网络投票时间：2025 年 11 月 24 日 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 11 月 24 日上午 9：15 至 9：25，9：30 至 11：30 和下午 13：00 至 15：00； 通过深圳证券交易所互联网投票系统（http://w ...

法律意见书 浙江天册律师事务所 关于浙江昂利康制药股份有限公司 2025 年第二次临时股东大会的 法律意见书 编号：TCYJS2025H1980 致：浙江昂利康制药股份有限公司 根据《中华人民共和国证券法》（下称"《证券法》"）、《中华人民共和国公司 法》（下称"《公司法》"）和《上市公司股东会规则》等法律、法规和规范性文件的 要求及《浙江昂利康制药股份有限公司章程》（下称"《公司章程》"）、《浙江昂利 康制药股份有限公司股东大会议事规则》（下称"《议事规则》"）的规定，浙江天册 律师事务所（下称"本所"）接受浙江昂利康制药股份有限公司（下称"昂利康"或"公 司"）的委托，指派俞晓瑜、郑忻律师（下称"本所律师"）参加昂利康 2025 年第二 次临时股东大会，对本次股东大会的召集和召开程序、出席会议人员资格、表决方式、 表决程序的合法性、有效性进行了认真审查，并出具本法律意见书。 本法律意见书仅供昂利康 2025 年第二次临时股东大会之目的使用。本所律师同意 将本法律意见书随昂利康本次股东大会其他信息披露资料一并公告。 本所律师根据相关法律法规的要求，按照律师行业公认的业务标准、道德规范和勤 勉尽责的精神，出席 ...

证券代码：002940 证券简称：昂利康 公告编号：2025-091 二、董事会会议审议情况 浙江昂利康制药股份有限公司 关于第四届董事会第十四次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江昂利康制药股份有限公司（以下简称"公司"）第四届董事会第十四次 会议（以下简称"会议"）通知于 2025 年 11 月 19 日以专人送达、邮件等方式发 出，会议于 2025 年 11 月 24 日以现场结合通讯表决的方式召开。本次会议的应 表决董事 7 人，实际参与表决董事 7 人，其中方南平先生、吴哲华先生、赵秀芳 女士以通讯方式参与表决。会议由副董事长吕慧浩先生主持。本次会议的召集、 召开符合《中华人民共和国公司法》和《公司章程》的规定，会议决议合法有效。 1、审议通过了《关于选举代表公司执行公司事务董事的议案》 根据《公司法》《公司章程》等规定，结合公司经营发展需要，董事会同意 选举董事长方南平先生为代表公司执行公司事务的董事，并担任法定代表人，任 期自本次董事会审议通过之日起至第四届董事会届满之日止。本次选举后，公司 ...

Group 1 - The core event on November 24 marks a significant "super meeting day" for multiple listed companies in Zhejiang, indicating a collective strategic decision-making process [1][3][4][5] - Companies like Huawai Technology, Anglikang, and Hechuan Technology are holding shareholder meetings to discuss future strategies and governance [1][6] Group 2 - There is a noticeable performance divergence among Zhejiang-listed companies, with Zhejiang Rongtai reporting a revenue of 960 million yuan for Q1-Q3 2025, a year-on-year increase of 18.65%, and a net profit of 203 million yuan, up 22.04% [7][8] - In contrast, Zhejiang Natural reported a revenue decline of 30.38% and a net profit drop of 40.63% for the same period [7][8] Group 3 - Emerging sectors are seeing accelerated investments, with Zhejiang Rongtai focusing on humanoid robot components, which are expected to experience significant growth [9][10] - The company is also involved in the new energy sector, with its mica products being crucial for electric vehicle battery safety, anticipating increased demand due to upcoming regulations [10] Group 4 - Institutional investors are showing strong interest in Zhejiang companies, with Zhejiang Rongtai projected to achieve revenues of 1.423 billion, 2.481 billion, and 4.178 billion yuan from 2025 to 2027, alongside net profits of 277 million, 485 million, and 839 million yuan respectively [11][12] - Zhejiang Pharmaceutical has also attracted attention, with forecasts estimating a net profit of 1.113 billion yuan for 2025 [13] Group 5 - Strategic upgrades are underway among Zhejiang-listed companies, focusing on optimizing corporate governance structures, as seen with Anglikang's adjustments to its supervisory framework [15] - International expansion is being pursued, with Zhejiang Rongtai establishing a production base in Thailand and Zhejiang Natural having subsidiaries in Vietnam and Cambodia [15][16] - Continuous investment in technological innovation is emphasized, with companies like Zhejiang Rongtai and Zhejiang Zhenyuan enhancing their R&D capabilities [16]

Core Points - On November 19, Angli康's stock dropped by 5.16%, trading at 40.47 CNY per share, with a transaction volume of 484 million CNY and a turnover rate of 6.31%, resulting in a total market capitalization of 8.164 billion CNY [1] - Angli康, established on December 30, 2001, and listed on October 23, 2018, is primarily engaged in the research, production, and sales of chemical raw materials and formulations, with its main revenue sources being formulations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1] Shareholder Analysis - Among Angli康's top ten circulating shareholders, a fund under China Europe Fund holds a significant position. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 3.351 million shares in the third quarter, now holding 3.0863 million shares, which accounts for 1.67% of the circulating shares. The estimated floating loss today is approximately 6.7899 million CNY [2] - The China Europe Medical Health Mixed A Fund (003095) was established on September 29, 2016, with a current scale of 16.977 billion CNY. Year-to-date returns are 20.05%, ranking 4065 out of 8138 in its category; the one-year return is 16.2%, ranking 4684 out of 8055; and since inception, the return is 107.2% [2] Fund Manager Information - The fund managers of the China Europe Medical Health Mixed A Fund (003095) are Ge Lan and Zhao Lei. As of the report, Ge Lan has a cumulative tenure of 10 years and 298 days, with the fund's total asset scale at 43.544 billion CNY, achieving the best return of 107.89% and the worst return of -35.13% during her tenure [3] - Zhao Lei has a cumulative tenure of 139 days, with the fund's total asset scale at 32.954 billion CNY, achieving the best return of 8.11% and the worst return of 7.8% during his tenure [3]

Core Viewpoint - Zhejiang Anglikang Pharmaceutical Co., Ltd. has received the approval notice for the listing application of the chemical raw material drug Bupivacaine from the National Medical Products Administration, which will enhance the company's product line and core competitiveness [1][4]. Group 1: Approval Information - The chemical raw material drug approved is Bupivacaine, with registration number Y20230001273 [1]. - The application for the drug was submitted in December 2023, accepted in January 2024, and recently approved [2]. Group 2: Product Application - Bupivacaine is primarily used in clinical settings for local anesthesia and postoperative analgesia [3]. Group 3: Impact on the Company - The approval of Bupivacaine will enrich the company's product line and enhance its core competitiveness [4].